The Luxembourg-domiciled Sicav will invest in “innovative” biotechnology and biotechnology-related companies that seek to address “high unmet medical needs around the world”.
The fund will target long-term growth within the “fast growing” biotechnology sector.
Ignacio de la Maza, head of continental Europe, wholesale and Latin America, said: “The fund will be managed by a team of experts with extensive scientific backgrounds and supported by the larger Janus Henderson healthcare investment team.”
It will be co-managed by Andy Acker and Dan Lyons, who have more than 40 years of combined experience investing in biotechnology.
International Adviser has contacted the firm about where the fund will be available.
The team uses its “statistical models and scientific expertise” to analyse the probability of success for drugs in clinical development.
It also integrates the “perspectives of physicians, patients, and payers to evaluate the commercial prospects for new and existing therapies”.
The fund invests at least 80% of its assets in biotechnology and biotechnology-related companies worldwide.
This includes companies in the Nasdaq Biotechnology Total Return index, those that develop small molecule or biologic drugs subject to approval of regulatory agencies, and firms that market products and services that aid in the research and development of small molecule or biologic drugs.